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ABSTRACT
Objective To assess the impact of daily cane use 
during gait in relation to pain, function, general health 
and energy expenditure among patients with knee 
osteoarthritis.
Method Sixty-four patients were randomly assigned to 
an experimental group (EG) or control group (CG). The 
EG used a cane every day for 2 months, whereas the 
CG did not use a cane in this period. The fi rst outcome 
was pain and the second were function (Lequesne 
and WOMAC), general health (SF-36) and energy 
expenditure (gas analysis during the 6-minute walk test 
(6MWT) with and without a cane). Evaluations were 
performed at baseline, 30 and 60 days.
Results The groups were homogeneous for all 
parameters at baseline. Compared with the CG, the 
EG signifi cantly improved pain (ES 0.18), function - 
Lequesne (ES 0.13), some domains of SF-36 (role 
physical, ES 0.07 and bodily pain, ES 0.08) and distance 
on the 6MWT with the cane (ES 0.16). At the end of 
the 6MWT with the cane, the EG signifi cantly improved 
energy expenditure (ES 0.21), carbon dioxide production 
(ES 0.12) and metabolic equivalents (ES 0.15) compared 
with the CG.
Conclusion A cane can be used to diminish pain, 
improve function and some aspects of quality of life 
in patients with knee osteoarthritis. The prescription 
of a cane should take into account the substantial 
increase in energy expenditure in the fi rst month of 
use, whereas energy expenditure is no longer a factor 
for concern by the end of the second month due to 
adaptation to cane use.
The trial was registered in clinicaltrials.gov 
(NCT00698412).
Osteoarthritis is one of the most common joint 
diseases worldwide and is characterised by the 
progressive degeneration of joint cartilage and 
decreased regeneration.1–3 osteoarthritis is a highly 
prevalent disease, with a low incidence before 
the age of 40 years, but progressively increasing 
thereafter.1–3 The prevalence of osteoarthritis is 
higher among women over the age of 50 years.1 4 
Joint damage from osteoarthritis progresses slowly 
and leads to joint stiffness, progressive deformity, 
joint instability and loss of function, thereby affect-
ing general health.5–7
Any disease in the knee can adversely affect 
gait, leading to reduced gait speed.8 Muscle 
weakness, pain, joint deformity and instabil-
ity in patients with knee osteoarthritis increase 
energy expenditure during gait.9 Patients with 
knee osteoarthritis generally shift their weight 
nearly completely to the medial compartment 
during gait.10 Therefore, decreasing the load on 
the medial compartment should be one of the 
treatment objectives for such patients.11 12 The 
use of a cane with the purpose of reducing the 
biomechanical load on the joints of the lower 
limb is part of the treatment for patients with 
knee osteoarthritis. This strategy is expected 
to increase both independence and tolerance 
to exercise, allowing a more effi cient gait, with 
a reduction in joint stress.12–15 A recent study 
assessing moments of knee strength with con-
tralateral and ipsilateral cane use in patients 
with knee osteoarthritis demonstrated that con-
tralateral cane use is more appropriate for such 
patients, as it is associated with lower peak force 
on the knee, thereby reducing the load on the 
medial compartment.11 16 Contralateral cane use 
also allows the affected lower limb to advance 
together with the upper limb carrying the cane, 
following a normal gait pattern, with pelvic rota-
tion matched by a counter rotation of the trunk 
and shoulder.12
Although most guidelines for the treatment of 
knee osteoarthritis recommend cane use,17–19 no 
studies assessing its effectiveness were found. 
Therefore, the aim of the present study was 
primarily to assess the impact of daily cane 
use during gait in relation to pain, and second-
arily the impact on function, general health and 
energy expenditure among patients with knee 
osteoarthritis.
METHODS
Study design and patients
A single-blind parallel group randomised controlled 
trial was carried out with a 2-month follow-up 
period. Sixty-four patients were selected from the 
rheumatology outpatient clinic. Inclusion criteria 
were: diagnosis of knee osteoarthritis based on the 
criteria of the American College of Rheumatology;20 
visual analogue scale (VAS) for knee pain score rang-
ing from 3 to 7 (maximum 10); stable doses of anti-
infl ammatory drugs; and no regular physical exercise 
in the month before the study. Exclusion criteria 
were: symptomatic heart disease; symptomatic dis-
ease of the lower limbs (other than knee osteoar-
thritis) or upper limb that would secure the cane; 
symptomatic lung disease; severe systemic disease; 
severe psychiatric illness; regular physical exercise 
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▷ General health—assessed using the short form 36 (SF-36) 
questionnaire,26 with overall scores ranging from 0 to 100 
(higher scores denote better general health);
▷ Energy expenditure—the subjects performed the 6-min-
ute walk test (6MWT) in compliance with the American 
Thoracic Society guidelines,27 using a portable metabolic 
system (model K4b2, COSMED – Cardio Pulmonary 
Diagnostic, Rome, Italy) consisting of a portable unit 
(dimensions 170×55×100 mm; weight 475 g) and battery 
(dimensions 170×48×90 mm; weight 400 g). This system is 
worn on the chest using a harness that fi ts over both shoul-
ders and around the waist, with the portable unit in the 
front pocket and battery in the back pocket. A fl exible rub-
ber facemask (Hans-Rudolph, Kansas City, Missouri, USA) 
is placed over the participant’s mouth and nose, secured by 
a mesh head cap and four clips. To avoid a learning effect, 
the test was carried out twice with the cane and twice 
without the cane28 on two separate days; the patient fi rst 
performed two tests under one condition and the other con-
dition was performed within a 7-day period, with at least 
one non-test day between tests. The order for the tests was 
determined randomly on the fi rst day. Between tests per-
formed on the same day, the patient was instructed to rest 
in a sitting position for at least 30 min or until respiratory 
and heart rate parameters returned to baseline values. The 
longer distance travelled on the 6MWT with and without 
cane use was used for analysis. Respiratory and metabolic 
parameters were assessed breath by breath. Before and 
after the 6MWT, heart rate response was measured using 
a heart monitor and knee pain experienced during the test 
was determined using the Borg scale,29 which was admin-
istered before and after the 6MWT;
▷ Cane use—patients in the EG received a chart on which 
they registered mean daily cane use;
▷ Consumption of non-steroidal anti-infl ammatory drugs 
(NSAID)—the patients were instructed to take sodium 
diclofenac (50 mg) every 8 h whenever they experienced 
pain equal to or above 7 on the VAS; patients could sus-
pend use of the medication when the pain reached 5 on 
the scale (this was carried out based on the patient’s judge-
ment). All patients received a chart to record the amount 
of NSAID drugs taken daily.
Statistical analysis
Sample size was calculated for repeated-measure analysis of 
variance (ANOVA) with two repetitions per situation, using the 
VAS for pain as the main parameter, with a SD of 2 cm.18 For 
the determination of a minimal effect of 2 cm, a 5% α error, 
20% β error and SD (σ) of 2 cm were established, using the for-
mula described by Filho.30 The calculation determined a mini-
mal sample of 27 patients per group. Considering a possible loss 
of 20%, it was determined that each group would comprise 32 
patients.
The following tests were used:
χ ▶ 2, Student’s t test and Mann–Whitney—to determine the 
homogeneity of the sample at the initial evaluation;
Repeated-measures ANOVA with Bonferroni adjust- ▶
ments—to determine differences in the outcomes between 
groups over time;
Effect size ( ▶ ω squared) and 95% CI—calculated for the 
parameters with statistically signifi cant differences between 
groups over time (ANOVA). The ω squared is an effect size 
measure associated with ANOVA. It is an overall estimate 
(three or more times per week for at least 3 months); drug injec-
tion in the knee in the previous 3 months; physiotherapy on the 
lower limbs in the previous 6 months; cane use in the previous 3 
months; inability to walk and geographical inaccessibility.
This study received approval from the ethics committee 
of the university and all patients signed a term of informed 
consent. A computer-generated randomisation list with a 1:1 
ratio (created by a statistician not involved in the trial) was 
used to allocate patients randomly to the experimental group 
(EG) and the control group (CG). Concealed randomisation 
was performed with opaque sealed envelopes and an inde-
pendent researcher not involved in eligibility assessment, out-
come assessment, or treatment kept the concealed assignment 
scheme in a locked cupboard in a central location. Allocation 
was revealed to the treating physiotherapist after the baseline 
evaluation.
This trial was registered in clinicaltrials.gov (NCT00698412) 
and this manuscript was prepared following the CONSORT 
statement.
Intervention
Wooden canes with a T-shaped handle were used. All patients 
were positioned standing comfortably erect, with arms relaxed 
alongside the body and wearing shoes with low heels. The cane 
was placed with the tip on the fl oor, 10 cm from the lateral mar-
gin of the ankle (towards the metatarsus) and a mark was made 
at the height of the distal fold of the wrist.21 22 After cutting the 
cane to the proper height, the elbow fl exion angle was mea-
sured, which should be between 20° and 30°; if this angle was 
not achieved, the cane was adjusted until it reached the proper 
elbow fl exion angle. The canes for the CG were locked in a cabi-
net by the primary researcher.
The EG took the cane home for day-to-day use for 2 months, 
whereas the participants in the CG were instructed to maintain 
their normal lives and did not use any auxiliary gait devices for 2 
months. The individuals in the CG maintained their usual treat-
ment for knee osteoarthritis and received their canes at the end 
of the study to begin day-to-day use.
On the fi rst evaluation, a physiotherapist offered a 5-min 
training period to each patient for instructions on using the cane 
on the contralateral side and setting the tip of the cane on the 
ground alongside the more symptomatic knee during the stance 
phase. During this training session, the patient walked along the 
same path determined for the subsequent walk test.
Clinical evaluations
Evaluations were carried out by a blinded assessor at baseline 
(T0), 30 (T30) and 60 (T60) days. The following demographic 
and clinical information were collected at baseline: radiological 
degree of osteoarthritis, dominant side, affected side, presence 
of pain, duration of osteoarthritis, weight and height.
Data were collected in the rheumatology outpatient clinic. 
The following outcomes were measured:
Primary outcome: ▶
▷ Pain—measured using a VAS ranging from 0 cm (no pain) 
to 10 cm (unbearable pain);23
Secondary outcomes: ▶
▷ Function—measured using the Lequesne knee 
questionnaire,24 with scores ranging from 0 to 24 points 
(lower scores denote better function), the Western Ontario 
and McMaster Universities (WOMAC) questionnaire),25 
with overall scores ranging from 0 to 96 points (lower 
scores denote better function);
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groups were found with regard to the WOMAC questionnaire 
or the role physical, mental health, vitality, general health, role 
emotional and social functioning domains of the SF-36 ques-
tionnaire (table 2).
Both groups behaved similarly over time regarding the param-
eters assessed during gait without the cane, with no statistically 
signifi cant differences between groups (table 3). The distance 
covered on the 6MWT with the cane increased signifi cantly in 
the EG over time in comparison with the CG (p<0.001). At the 
end of the 6MWT, participants in the EG exhibited statistically 
signifi cant improvements over time regarding the Borg scale for 
pain (p=0.001), energy expenditure (oxygen consumption (VO2); 
p=0.001), carbon dioxide production (VCO2; p<0.001) and met-
abolic equivalents (METS; p<0.001) in comparison with the CG 
(table 3).
Table 4 shows the effect size (ω squared) and 95% CI for all 
the parameters that were signifi cantly different between groups 
over time (ANOVA).
for both follow-up points and the interpretation is small 0.01, 
medium 0.06 and large 0.14;31
Paired Student’s t test—intragroup analysis was performed  ▶
for the parameters measured during the 6MWT with and 
without cane use for the determination of differences within 
each group.
Using intention-to-treat analysis, the data from all patients 
initially enrolled were analysed. For cases in which there was 
interruption of treatment, the patients were fi rst asked to come 
in and only perform the evaluations. For patients who refused to 
return for the evaluations, the last data collected were repeated 
in the subsequent evaluations.
RESULTS
The data were collected between 2007 and 2009. Three hun-
dred and twenty-three patients with knee osteoarthritis were 
interviewed individually until fi nding 64 patients who satisfi ed 
the inclusion criteria. These patients were randomly allocated 
to the two groups (experimental and control) immediately fol-
lowing the fi rst evaluation. Figure 1 displays a fl owchart of 
the study. The main reason why patients refused to partici-
pate in the study was because they did not want to use a cane 
(n=113).
At baseline, no statistically signifi cant differences were found 
between groups regarding demographic and clinical characteris-
tics (table 1) or the parameters assessed on the 6MWT with and 
without cane use (table 3). Eighty-nine per cent of the patients 
were women and 11% were men; 79% were right-handed; 62% 
had osteoarthritis in the right knee and 38% had osteoarthritis 
in the left knee; 53% had grade II osteoarthritis and 47% had 
grade III.
Comparisons between groups over time
The EG exhibited statistically signifi cant improvements over 
time in comparison with the CG with regard to pain mea-
sured by VAS with p<0.001 (fi gure 2) and SF-36 bodily pain 
domain (p<0.001) and function measured by the Lequesne 
knee questionnaire (p=0.001) and SF-36 physical function 
domain (p<0.001). No statistically signifi cant differences between 
Figure 1 Flowchart of the study. CG, control group; EG, experimental group; T0, baseline; T30, evaluation after 30 days; T60, evaluation after 
60 days.
Table 1 Demographic and clinical characteristics at baseline
 CG EG p Value
Age (years) 62.56 (5.88) 61.75 (5.92) 0.899
Disease duration (years) 6.53 (3.87) 6.06 (2.82) 0.581
Height (cm) 1.56 (0.63) 1.58 (0.66) 0.253
Weight (kg) 72.34 (9.09) 72.50 (7.55) 0.941
BMI (kg/m2) 29.54 (3.42) 29.01 (2.83) 0.200
VAS for pain (range 0–10 cm) 5.48 (1.23) 5.63 (1.02) 0.619
Lequesne (0–24) 14.59 (3.6) 15.7 (3.3) 0.198
WOMAC (0–96) 47.69 (14.7) 54.1 (14.2) 0.111
SF-36 (0–100)
 Physical functioning 28.9 (13.0) 35.9 (17.5) 0.127
 Role physical 22.7 (24.07) 23.4 (31.7) 0.912
 Bodily pain 46.1 (15.3) 48.7 (15.1) 0.571
 General health 57.3 (21.0) 49.0 (21.7) 0.255
 Vitality 38.8 (22.1) 40.5 (25.2) 0.502
 Social functioning 48.8 (20.0) 51.7 (22.57) 0.405
 Role emotional 24.1 (30.6) 25.5 (31.9) 0.872
 Mental health 44.6 (22.6) 46.4 (24.7) 0.968
CG, control group; EG, experimental group; BMI, body mass index; SF-36, short form 
36; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities 
questionnaire.
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The results demonstrate that cane use by patients with knee 
osteoarthritis is an ongoing process of adaptation. All patients 
exhibited less effi ciency in the fi rst month, as demonstrated by 
the shorter distance covered and greater energy expenditure on 
the 6MWT. However, at the end of the second month of cane 
use, they were able to walk with the cane approximately the 
same distance and with less energy expenditure than without 
the cane and also experienced less pain. The intragroup com-
parison clearly shows the behaviour of each group and reveals 
the adaptation process that occurred in the EG. During this 
adaptation process, it is of extreme importance for healthcare 
professionals to educate patients regarding the diffi culties they 
will face, especially in the fi rst month. Such education could lead 
to better patient adherence to using a cane.
Pain is the main complaint among patients with knee osteoar-
thritis and because of this it was chosen as the primary outcome 
of this study. While the patients in the present study initially 
exhibited pain similar to that found in other studies address-
ing the non-pharmacological treatment of osteoarthritis,32 33 
some studies report higher mean values34 and others report 
lower mean values,35 36 which demonstrates the variability of 
this parameter.37 The reduction in pain in the EG was similar 
to that reported in other studies involving patients with knee 
osteoarthritis.34 36 38
The patients in the present study were overweight, but 
other studies on knee osteoarthritis have described similar fi nd-
ings.35 36 39 40 While obesity has been described as a risk fac-
tor for the development of osteoarthritis, it is not yet clear how 
excess weight infl uences the development or progression of the 
disease.41
The patients in this study were considered to have grades 
II and III in radiological evaluation, taking into account that 
only patients with a knee pain score ranging from 3 to 7 were 
included, our sample was composed of patients with moderate 
involvement of osteoarthritis and none of them were eligible for 
knee surgery.
Function was compromised, as the Lequesne scores classifi ed 
the patients as having moderate to severe limitation. In the lit-
erature, lower scores are found for the population with knee 
osteoarthritis.33 34 36 42 The improvement in this parameter at the 
end of treatment was less than that found in a previous study 
in which patients were treated with hyaluronate with the same 
Comparisons with and without cane on 6MWT
Control group
The CG covered a greater distance (p<0.001) on the 6MWT 
when walking without the cane at T0, T30 and T60 (fi gure 3A). 
Regarding the Borg score, less pain was found at the end of 
the 6MWT with the cane at T0 (p=0.03). The initial heart rate 
was higher at the beginning of the test with the cane at T30 
(p=0.029) and the fi nal heart rate was always higher when the 
test was performed with the cane (T0 p=0.04; T30 p=0.04; T60 
p=0.011). The fi nal VO2 (p<0.001), VCO2 (p<0.001) and METS 
(p<0.001) were signifi cantly higher at the end of the 6MWT 
with the cane; these differences were detected on all three eval-
uations (fi gure 3B).
Experimental group
The EG covered a greater distance on the 6MWT at T0 without 
the cane (p<0.001); however, no statistically signifi cant differ-
ence was found between the distance covered with and without 
the cane at T30 and T60 (fi gure 3C). The patients had less pain 
at the end of the 6MWT with the cane at T30 (p=0.017) and 
T60 (p=0.001). The heart rate was higher at the beginning of the 
6MWT with the cane on the three evaluations (T0 p=0.028; T30 
p=0.015; T60 p=0.050). The heart rate was higher at the end of 
the 6MWT with the cane only at T0 (p=0.006). With the cane, 
the EG had signifi cantly higher VO2, VCO2 and METS values 
(p<0.001) at the end of the 6MWT at T0 and T30 (fi gure 3D).
NSAID intake and cane use
Fewer NSAID pills were consumed in the EG compared with 
the CG at T30 (p=0.010) and T60 (p<0.001). Average cane use in 
the EG was 45 min/day in the fi rst month and 74 min/day in the 
second month (table 2).
DISCUSSION
The authors were surprised to discover that, despite the fact 
that cane use goes back as far as ancient Egypt, very few studies 
have been carried out on this topic. Most investigations have 
been cross-sectional studies and offer no comparisons of cane 
use with other interventions or with no intervention at all.11 12 16 
The present investigation is thus the fi rst study to assess the 
effectiveness of this widely used gait-assistance device among 
patients with knee osteoarthritis.









(ANOVA)CG EG CG EG CG EG
VAS for pain (range 0–10 cm) 5.48 (1.23) 5.63 (1.02)  6.05 (1.35)  5.28 (0.92) −0.77 5.95 (1.40) 3.84 (1.44) −2.11 <0.001*
Lequesne (0–24) 14.59 (3.6) 15.7 (3.3) 14.6 (3.37) 14.28 (3.53) −0.32 1s5.09 (3.60) 12.56 (3.47) −2.53 <0.001*
WOMAC (0–96) 47.69 (14.7) 54.1 (14.2) 47.7 (15.36) 49.56 (15.05) 1.86 47.28 (14.71) 46.22 (15.88) −1.06 0.051
SF-36 (0–100)
 Physical functioning 28.9 (13.0) 35.9 (17.5) 33.9 (15.59) 37.13 (14.78) 3.23 35.94 (18.94) 45.00 (15.08) 9.06 0.078
 Role physical 22.7 (24.07) 23.4 (31.7) 24.34 (31.51) 32.97 (29.64) 8.63 26.06 (28.33) 42.81 (30.21) 16.75 0.001*
 Bodily pain 46.1 (15.3) 48.7 (15.1) 47.7 (23.00) 53.16 (17.59) 5.46 46.03 (20.34) 60.19 (19.38) 14.16 <0.001*
 General health 57.3 (21.0) 49.0 (21.7) 51.7 (18.97) 55.97 (19.99) 4.27 56.81 (23.55) 58.87 (24.13) 2.06 0.056
 Vitality 38.8 (22.1) 40.5 (25.2) 41.6 (22.70) 46.13 (20.94) 4.53 38.59 (28.40) 54.09 (26.28) 15.5 0.658
 Social functioning 48.8 (20.0) 51.7 (22.57) 49.5 (20.80) 54.89 (20.02) 5.39 49.22 (19.56) 57.16 (17.29) 7.94 0.597
 Role emotional 24.1 (30.6) 25.5 (31.9) 19.3 (23.90) 36.71 (31.62) 17.41 24.90 (29.37) 42.98 (29.63) 18.08 0.893
 Mental health 44.6 (22.6) 46.4 (24.7) 46.1 (18.42) 52.00 (21.82) 5.9 51.10 (20.79) 58.81 (19.62) 7.71 0.568
Use of NSAID (pills/month), median — — 25 19 25 16.5 — —
p Value (t test) — —  0.010* — <0.001* — —
Cane use (min/day) — — — 45 (9.80) — — 74 (13.24) — —
*Statistically signifi cant p value (<0.05).
ANOVA, analysis of variance; BMI, body mass index; EG, experimental group; CG, control group; NSAID, non-steroidal anti-infl ammatory drug; T0, baseline; T30, evaluation after 30 
days; T60, evaluation after 60 days; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities questionnaire.
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A signifi cant improvement was found in the bodily pain and 
physical function subscales of the SF-36 questionnaire, which 
was probably related to the VAS and Lequesne fi ndings. Studies 
on knee osteoarthritis describe quite varied scores in general 
health status following treatment, which hinders comparisons. 
However, the improvement in the present study was similar to 
that described in previous studies involving different types of 
treatment for patients with knee osteoarthritis.36 43 44
As all patients used the same type of cane, there were no 
differences in this aspect that might infl uence the results. The 
choice of cane length based on the distal fold of the wrist 
was taken from a previous study, which had methodologi-
cal fl aws, but was the only study ever carried out to measure 
energy expenditure in patients with knee osteoarthritis.22 
Moreover, care was taken to determine the angle of elbow 
fl exion after cutting the cane in order to prevent elbow and 
shoulder injuries.
On the 6MWT without the cane at baseline, patients cov-
ered a distance that was less than expected for healthy 
adults,45 but similar to what is reported for patients with knee 
 osteoarthritis.46 47 All patients covered similar distances at all 
evaluation times when walking without the cane. The patients 
in both groups covered a signifi cantly shorter distance at base-
line with the cane than without it. Throughout the study, how-
ever, adaptation to cane use gradually allowed the patients in 
the EG to walk signifi cantly farther, until reaching a distance 
similar to that covered without the cane.
Cane use at baseline led to greater energy expenditure in both 
groups, as also demonstrated in a previous study.22 Although 
one previous study assessing energy expenditure during cane-
assisted gait in patients with knee osteoarthritis was found,22 
that study assessed only the initial impact of cane use on energy 
expenditure, with the objective of determining whether or not 
cane length infl uenced energy expenditure in this population. 
The authors reported an increase in energy expenditure during 
cane-assisted gait, similar to that found in the baseline evalua-
tion of the present study.22
An important fi nding in our study was pain following the 
walk test, a factor that could infl uence functionality. The EG 
patients experienced less pain at T30 and T60 when tested using 
the cane. This probably demonstrates adaptation to cane use, 
by reducing the weight load on the affected joint during gait, 
thereby reducing pain following the walk test.
The EG patients were asked to use the cane only outside the 
home. The limited amount of usage time may refl ect the fact 
that these patients did not often leave their homes.
follow-up period.33 If the treatment period in the present study 
had been longer, it is likely that a more substantial improvement 
would have been achieved.
The patients in the present study exhibited considerable 
functional limitation, with WOMAC scores slightly higher 
than those described in other studies, despite the fact that 
the present sample was younger.36 42 Although the EG tended 
towards functional improvement with cane use, no signifi cant 
difference was found between the groups. This may have been 
due to different reasons, such as the short follow-up period 
or chance.
Table 4 Effect size and 95% CI for the parameters that were 
statistically signifi cantly different between groups with ANOVA
 ES (95% CI)
Pain (VAS) 0.18 (−0.42 to 0.87)
Lequesne 0.13 (−0.11 to 0.42)
SF-36
 Physical functioning 0.07 (−0.21 to 0.39)
 Bodily pain 0.08 (−0.68 to 1.54)
6MWT with cane
 Distance (m) 0.16 (0.01 to 0.69)
 Borg fi nal pain 0.09 (0.01 to 0.84)
 VO2 fi nal (l/min) 0.21 (0.12 to 0.90)
 VCO2 fi nal (l/min) 0.12 (−0.96 to 1.50)
 METS fi nal 0.15 (−0.12 to 1.79)
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Regarding NSAID intake at T30, patients in both the EG and 
CG groups took fewer tablets compared with patients with 
knee osteoarthritis in other studies.38 39 However, patients in 
the EG gradually reduced their NSAID intake during the study. 
This may refl ect decreasing pain in the EG, whereas patients in 
the CG showed little change in the intake of pain medications. 
This reduction in NSAID use by the EG may be benefi cial with 
regard to the risk of gastrointestinal and renal complications 
associated with the continued use of this type of medication in 
older patients.48
Regarding the effect size, we found a medium or large effect 
for all the parameters that were statistically signifi cant with 
ANOVA; however, we have to view these data with caution 
because for some of this parameter the 95% CI included the 
zero value, which means that it is not statistically signifi cant 
at a level of 0.05. It is important to say that the CI represents 
the precision with which we are able to report the effect size, 
and the larger the sample, the more precise the estimate.
The results of the present study can be extrapolated to a 
population with knee osteoarthritis with similar characteristics 
to the sample of the study. It cannot be widely extrapolated to 
other populations with other knee problems or other degrees of 
severity, but it is possible that cane use would also benefi t those 
populations. One of the limitations of the present study was 
the short follow-up time, considering the fact that these patients 
could use a cane for the rest of their lives. It is possible that a 
longer follow-up could lead to continued improvement. Further 
studies are needed to assess the impact of long-term cane use on 
these patients as well as its short-term and long-term impact on 
patients with other rheumatic conditions.
In conclusion, a cane is a gait-assistance device that can be used 
to diminish pain in patients with knee osteoarthritis in addition to 
improving function and enhancing aspects of quality of life. The 
prescription of a cane should take into account the substantial 
increase in energy expenditure in the fi rst month of use, whereas 
energy expenditure is no longer a factor for concern by the end of 
the second month as a result of adaptation to cane use.
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